Core Viewpoint - The company, Sichuang Zhiliang (300078), forecasts a net profit loss attributable to shareholders of 41.25 million to 82.49 million yuan for the year 2025, indicating a reduction in losses compared to the previous year's loss of 100 million yuan [1] Group 1: Financial Performance - The expected net profit loss for 2025 is between 41.25 million yuan and 82.49 million yuan, showing an improvement from the previous year's loss of 100 million yuan [1] - The company aims to enhance its profitability through strategic asset divestiture [1] Group 2: Business Strategy - The company plans to sell its 100% stake in the subsidiary, Yihui Technology, to Cangnan Shanhai Digital Technology Co., Ltd., with the transaction expected to be completed by August 2025 [1] - This divestiture is intended to remove underperforming assets from the company, thereby optimizing its business structure and facilitating a transformation and upgrade of its operations [1]

思创智联（300078）(300078.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损 4124.57万元—8249.15万元;扣除非经常性损益后的净亏损1.18亿元至2.19亿元。 报告期内，公司将智慧医疗板块业务子公司医惠科技100%股权出售给苍南县山海数字科技有限公司， 并于2025年8月完成交割，交易完成后，公司不再持有医惠科技股权，医惠科技不再纳入公司合并报表 范围。近年来，公司智慧医疗业务受行业竞争激烈、业务调整等多方面因素影响导致持续亏损，对公司 的整体经营发展造成了较大不利影响。本次交易将经营状况不佳的资产从公司剥离，旨在提升公司盈利 能力，实现业务结构优化和转型升级。 ...

Core Viewpoint - The company, 思创智联, anticipates a net loss attributable to shareholders ranging from 41.25 million to 82.49 million yuan for the fiscal year 2025, with a net loss excluding non-recurring gains and losses projected between 118 million and 219 million yuan [1] Group 1: Financial Performance - The company expects a significant net loss for 2025, indicating ongoing financial challenges [1] - The projected losses highlight the impact of intense industry competition and business adjustments on the company's financial health [1] Group 2: Business Strategy - The company plans to divest its 100% stake in its subsidiary, 医惠科技, to 苍南县山海数字科技有限公司, with the transaction expected to be completed by August 2025 [1] - This divestiture aims to remove underperforming assets from the company's balance sheet, thereby enhancing profitability and facilitating business restructuring and transformation [1]

Core Insights - The stock price of Sichuang Medical has plummeted due to a criminal investigation initiated by the Hangzhou Public Security Bureau regarding fraudulent securities issuance, marking another significant crisis for the company after a hefty fine of 85.7 million yuan imposed by the Zhejiang Securities Regulatory Bureau last year [1][2]. Financial Fraud - Regulatory investigations have uncovered a chain of fraud involving Sichuang Medical, where in 2020, the company inflated profits by 83.94 million yuan, accounting for 67% of the total profit for that period, through its wholly-owned subsidiary, Yihui Technology [2]. Business Impact - The repercussions of the fraud have severely affected the core business of Yihui Technology, which has faced repeated failures in public hospital tenders due to reputational damage. The company's revenue is projected to drop to 169 million yuan in 2024, with a net loss of 320 million yuan, representing a nearly 60% decline from 417 million yuan in 2022 [3]. Strategic Restructuring - On May 30, Sichuang Medical announced the sale of Yihui Technology to a state-owned enterprise for nearly 300 million yuan, marking a complete exit from the smart healthcare sector. The company stated that the divestiture was necessary to concentrate resources on developing business intelligence [4]. Transition Challenges - Following the focus shift to business intelligence, Sichuang Medical aims to leverage its leading global EAS hard tag production capacity and RFID technology. However, the business intelligence segment is expected to see a revenue decline of 15% in 2024, with a gross margin drop of 4.83 percentage points to 21.54%. Despite an increase in revenue share to 72.5%, growth momentum remains insufficient [5].

Group 1 - The core opinion of the article is that the legal opinion issued by Beijing Deheng (Hangzhou) Law Firm confirms the legality and compliance of the major asset sale and related transactions of Sichuang Medical Technology Co., Ltd [1][4][14] - The transaction involves the transfer of 100% equity of Yihui Technology by Sichuang Medical to Shanhai Digital for a total price of 299.5995 million yuan [5][10] - The payment for the transaction will be made in cash, with the entire amount to be paid before the completion of the asset transfer [6][10] Group 2 - The legal opinion states that the transaction has received necessary approvals and authorizations from the company's board and shareholders [8][10][14] - The transfer of ownership for the assets has been completed, and the relevant registration procedures have been carried out [11][14] - There are no significant discrepancies between the actual situation of the transaction and the previously disclosed information [11][14] Group 3 - The company has confirmed that there have been no changes in the board of directors, supervisors, or senior management personnel of either the listed company or the target company since the disclosure of the restructuring report [12][14] - The transaction does not involve the transfer of debts and liabilities of the target company, and there have been no instances of fund occupation or guarantees provided to related parties during the transaction process [13][14] - All parties involved in the transaction are fulfilling their commitments and agreements as per the signed equity transfer agreement [13][14]

Core Viewpoint - The sale of 100% equity in Yihui Technology by Sichuang Medical to Shanhai Digital for approximately 299.6 million RMB marks a strategic shift for Sichuang Medical, allowing it to divest from its underperforming smart healthcare business and focus on the commercial intelligence sector [1][2]. Group 1: Company Strategy - The primary objective of the transaction is to concentrate resources and funding on the commercial intelligence business, which is expected to optimize the company's business structure and promote high-quality development [1][2]. - After the sale, Yihui Technology will no longer be included in the consolidated financial statements, which is anticipated to improve the company's financial condition and performance metrics [1][3]. - The commercial intelligence business is based on EAS and RFID research and production, providing deep IoT solutions across various industries, with a strong market position in both EAS and RFID sectors [2]. Group 2: Financial Impact - In the period from January to October 2024, Yihui Technology reported revenues of 111 million RMB and a net loss of 316 million RMB, significantly dragging down the overall performance of Sichuang Medical [1]. - The divestiture is expected to enhance asset quality and profitability, as well as increase working capital reserves, thereby supporting the company's focus on commercial intelligence [1][2]. Group 3: Market Position and Future Outlook - The strategic support from state-owned enterprises is crucial for the development of the smart healthcare sector, highlighting the importance of national strategic technology forces [2]. - The transaction is viewed as a positive move that will not compromise the integrity of the company's operations but rather enhance profitability and long-term shareholder value [3].